Core Viewpoint - Three Leaf Clover Biotech-B (02197) has seen a significant stock price increase, with a nearly 12% rise during trading and over a 200% increase in the past month, indicating strong market interest and potential investor confidence [1] Company Overview - Three Leaf Clover Biotech-B is a biotechnology company focused on the development of respiratory vaccines, with a differentiated core technology platform and product pipeline in the industry [1] - The company is one of the first biotech firms to list under the Hong Kong Stock Exchange's 18A rules, attracting notable institutional investors such as Hillhouse Capital and Temasek as cornerstone investors [1] Clinical Development - The company has completed the enrollment of the first batch of subjects in Phase I clinical trials for its respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) [1] - The vaccine candidates utilize a stabilized PreF trimer subunit vaccine antigen based on the company's proprietary protein trimerization vaccine technology platform [1] Technology Platform - The Trimer-Tag™ platform developed by the company mimics the structure of human collagen trimer, allowing for the stabilization of any viral antigen into a natural trimeric form, which has been validated for the development of vaccines against various viruses, including COVID-19 and RSV [1]
港股异动 | 三叶草生物-B(02197)盘中涨近12% 将于下周二公布中期业绩 公司专注呼吸道疫苗研发